Home > Boards > US Listed > Medical - Equipment > Edwards Life Sciences LLC (EW)

EW, another guidance hit

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
m177 Member Profile
 
Followed By 14
Posts 4,149
Boards Moderated 0
Alias Born 11/24/07
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/14/2019 6:00:57 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/14/2019 6:00:42 PM
Annual Report of Employee Stock Plans (11-k) Edgar (US Regulatory) - 6/14/2019 5:24:44 PM
Annual Report of Employee Stock Plans (11-k) Edgar (US Regulatory) - 6/14/2019 5:23:13 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/5/2019 6:00:57 PM
Edwards Lifesciences To Present At The Goldman Sachs 40th Annual Global Healthcare Conference PR Newswire (US) - 6/4/2019 11:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/3/2019 4:52:57 PM
Edwards Lifesciences Recommends Stockholders Reject "Mini-Tender Offer" By TRC Capital Corporation PR Newswire (US) - 6/3/2019 4:15:00 PM
Specialized Disclosure Report (sd) Edgar (US Regulatory) - 5/31/2019 4:02:24 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/30/2019 6:16:36 PM
Edwards Announces Milestones For Transcatheter Mitral Program PR Newswire (US) - 5/22/2019 2:30:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/17/2019 6:00:11 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/15/2019 6:58:22 PM
Edwards Lifesciences' Every Heartbeat Matters Charitable Initiative On Track to Impact 1.5 Million Underserved People By 2020 PR Newswire (US) - 5/15/2019 9:15:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/14/2019 7:37:07 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/14/2019 7:05:09 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/14/2019 7:01:06 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/14/2019 6:40:22 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/14/2019 6:25:09 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/13/2019 6:58:21 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/13/2019 6:40:43 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/13/2019 6:39:37 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/13/2019 6:38:17 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/13/2019 6:36:36 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/13/2019 6:36:35 PM
m177   Tuesday, 10/09/12 10:00:35 AM
Re: None
Post # of 276 
EW, another guidance hit

Co issues downside guidance for Q3 (Sep), sees Q3 (Sep) revs of $448 mln vs. $476.56 mln Capital IQ Consensus Estimate. This represents a growth rate of approximately 9 percent, or 14 percent excluding the impact of foreign exchange. This compares to the Company's guidance of $465 million to $485 million provided during its second quarter earnings conference call on July 24, 2012. Transcatheter heart valve sales were below expectations for the third quarter, with global sales estimated at $124 million, including U.S. sales of $55 million. "In Europe, austerity measures tempered procedural volumes, resulting in underlying sales comparable to the same period a year ago. In the U.S., we are pleased with the overall progress of the launch, with training of commercial sites continuing as planned and procedural success rates remaining high. However, under the provisions of the National Coverage Decision, there was no reimbursement for inoperable patients without femoral access. A clinical protocol that would allow reimbursement for this sizable group of patients was expected earlier; it is now anticipated in the next several weeks. Additionally, due to the requirement that a full Heart Team be present for every procedure, summer vacations had a more pronounced effect.... Despite the third-quarter sales shortfall, we anticipate a strong rebound in the fourth quarter. The pending FDA approval to expand the indication to treat U.S. high-risk patients with SAPIEN, as well as the recent addition of our larger 29mm valve and a third delivery approach to our clinical trial, will make this therapy available to a considerably broader group of patients. Assuming this FDA approval happens early this quarter, for full-year 2012, we expect to achieve the low end of both our current global THV sales guidance of $550 million to $600 million, and our U.S. THV sales guidance of $240 million to $260 million. We remain enthusiastic about the potential of this transformative technology to improve the lives of many of the patients who suffer from severe aortic stenosis..."



Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist